Processing...
Clinical Trials for Cervical Cancer
Search
Search
There are 249 active trials for advanced/metastatic cervical cancer.
Click on a trial to see more information.
249 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with relapsed/refractory metastatic RCC (clear cell or papillary), EBV-associated NPC, or advanced NHL (including DLBCL, FL, MCL) receive GEN1160 (PRO1160), a CD70-directed antibody–drug conjugate delivering an exatecan topoisomerase-1 inhibitor payload, given IV Day 1 of 21-day cycles; expansion focuses on DLBCL NOS after ≥2 prior regimens including CD20 chemoimmunotherapy. Excludes prior CD70 therapy/topo-1 ADCs, recent transplants/intensive therapy, active CNS disease (expansion), and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT05721222
HealthScout AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.
ClinicalTrials.gov ID: NCT03968406
HealthScout AI summary: Adults with recurrent gynecologic cancers—platinum-resistant high‑grade serous ovarian/fallopian tube/primary peritoneal, selected endometrial, and cervical cancers—receive IMGN151, an investigational FRα‑targeted antibody–drug conjugate (biparatopic anti‑FRα linked to maytansinoid DM21) given IV every 3 weeks. Expansion includes cohorts with/without prior FRα therapy (where allowed), with requirements such as measurable disease and prior checkpoint inhibitor use in eligible endometrial and cervical cancer.
ClinicalTrials.gov ID: NCT05527184
HealthScout AI summary: Adults with locally advanced/metastatic solid tumors (ECOG 0–1) who have progressed on prior therapy and lack standard options receive SPX‑303 monotherapy, a first‑in‑class bispecific antibody targeting LILRB2 (ILT4) on myeloid cells and PD‑L1, given IV every 3 weeks. Excludes active/unstable CNS disease and prior ILT2/ILT4/HLA‑G–targeted therapy; allows well-controlled HIV.
ClinicalTrials.gov ID: NCT06259552
HealthScout AI summary: Adults with untreated recurrent/metastatic HNSCC (non‑nasopharyngeal) eligible for pembrolizumab are randomized to pembrolizumab alone versus pembrolizumab plus BI 770371 (anti‑SIRPα blocking the CD47–SIRPα “don’t‑eat‑me” axis) with or without cetuximab (anti‑EGFR). Prior definitive therapy is allowed if >6 months from progression; requires measurable disease and tumor tissue, and excludes prior PD‑(L)1 or SIRPα/CD47 agents and active brain metastases.
ClinicalTrials.gov ID: NCT06806852
HealthScout AI summary: Adults with recurrent/metastatic, incurable HNSCC requiring palliative RT and having two index lesions (one for RT, one for serial biopsy) receive pembrolizumab plus the investigational oral AXL/MerTK (TAM) inhibitor INCB081776, with RT delivered to one lesion excluded from efficacy assessments. Suitable for patients recovered from prior therapies, without autoimmune disease requiring immunosuppression or significant retinal disorders.
ClinicalTrials.gov ID: NCT06308913
HealthScout AI summary: Adults with incurable, locally advanced/metastatic Nectin-4–positive solid tumors—emphasizing relapsed/refractory urothelial cancer—receive RNDO-564 weekly as monotherapy or combined with pembrolizumab every 3 weeks. RNDO-564 is a fully human CD28 × Nectin-4 costimulatory bispecific antibody intended to deliver localized CD28 T‑cell costimulation at Nectin-4–expressing tumors; early cohorts include multiple Nectin-4–associated cancers, with randomized dose-optimization in urothelial cancer.
ClinicalTrials.gov ID: NCT07218003
HealthScout AI summary: Adults with advanced/metastatic urothelial carcinoma or squamous cell carcinomas (lung, esophagus, cutaneous, head/neck, anogenital) after standard therapies receive single‑agent EVOLVE104, a trispecific T‑cell engager targeting ULBP2/5/6 with CD3 binding and CD2 costimulation. Open‑label dose escalation and expansion assess safety, PK, and preliminary efficacy, with treatment continued until progression or intolerance.
ClinicalTrials.gov ID: NCT07217171
HealthScout AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).
ClinicalTrials.gov ID: NCT07030257
HealthScout AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.
ClinicalTrials.gov ID: NCT07090499